Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome

NCT01569464 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01569464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01569464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
April 30, 2013
Enrollment
150 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome